Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent - Wikidata - awgldk - TriplyDB

Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent

Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent

http://www.wikidata.org/entity/Q24656023

about

Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors Suppression of coronavirus replication by cyclophilin inhibitors Curing a viral infection by targeting the host: the example of cyclophilin inhibitors Cyclosporine Inhibits Flavivirus Replication through Blocking the Interaction between Host Cyclophilins and Viral NS5 Protein Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics Rheumatoid arthritis in patients with HIV: management challenges Targeting Mitochondria and Reactive Oxygen Species-Driven Pathogenesis in Diabetic Nephropathy Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175 DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A A novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile.Host and viral determinants of Mx2 antiretroviral activity Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.Potent strategy to inhibit HIV-1 by binding both gp120 and gp41.Delaying reverse transcription does not increase sensitivity of HIV-1 to human TRIM5α.Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection.Highly potent chimeric inhibitors targeting two steps of HIV cell entry Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.Semen of HIV-1-infected individuals: local shedding of herpesviruses and reprogrammed cytokine network.Redoxal, an inhibitor of de novo pyrimidine biosynthesis, augments APOBEC3G antiviral activity against human immunodeficiency virus type 1.The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen HIV-1 imposes rigidity on blood and semen cytokine networks.Identification of HIV inhibitors guided by free energy perturbation calculations.Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice.Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.HIV-1 uncoating: connection to nuclear entry and regulation by host proteins.The role of immunophilins in viral infection.Synergistic Antiviral activity of Sofosbuvir and Type -I Interferons (α and β) against Zika virus.Structure-activity relationship studies of indole-based compounds as small molecule HIV-1 fusion inhibitors targeting glycoprotein 41.The host proteins transportin SR2/TNPO3 and cyclophilin A exert opposing effects on HIV-1 uncoating.Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid Suppression of feline coronavirus replication in vitro by cyclosporin A.Potent lentiviral restriction by a synthetic feline TRIM5 cyclophilin A fusion.An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1.Structure-activity relationships of a novel capsid targeted inhibitor of HIV-1 replication.

P2860

Q24645702-95118D16-A762-49C2-ADD9-94F2184657A2 Q26825245-F88EFFA4-C4D8-4A14-B156-C825BE038006 Q26828727-8555E376-3604-4427-AA61-7BEF759AF8F2 Q27488982-76DCEEE5-0F63-48ED-9111-A085C3C7B1EA Q27489037-6BA9557B-9EE5-45B5-A6BE-E961EF737D7F Q28075624-B246D7E4-98AA-4ED0-9725-FE001EFF638A Q28083205-C087DC32-4152-4579-A35C-2055B8A5A9FF Q28551538-4578C507-28DC-42FF-A305-BF54FA8E63D9 Q28748683-C2DD4F19-3A12-47BE-8F73-DA435AC778AE Q30429621-A6AD44E3-5EFD-4A6F-8C24-13BD35BDE97B Q33900299-013C644E-89A3-4367-8703-C30A2020CFBE Q33962846-9831D41C-CACB-408A-97D3-CBB0F43C0768 Q34483474-5A560135-3D78-43B0-939F-514BD71F414C Q34548171-B7EE8208-5CAF-4AC3-B71C-1CA6C92D20C4 Q35108069-C4642EB0-43A3-4849-A22C-CABF1379C027 Q35150195-8F0887E9-0DAA-4D4F-A324-813905FBF436 Q35451347-A9423449-E083-4BB1-924F-4D9BC15078B5 Q35623739-7BB39D51-E922-4CEB-AEE0-EDAED4D073B6 Q35682519-5583455A-7AB0-419E-87B2-7710393EE1D4 Q35742761-64996C00-6D75-4BEA-B2A5-DD61387A5922 Q36075908-34C5D4DC-1496-4BA8-9750-05254AEC195B Q36076011-A3849B64-51A9-4BCE-9DAD-F6149DD74C20 Q36102252-3F371D56-D812-45CA-AE7A-705EAC6947A6 Q36385010-3013B6B7-8621-43E2-A2E6-CA077E9C8565 Q36708826-D3045456-5852-4212-8B02-F66D51B5AD73 Q36990220-64A4999D-D2B8-45FB-BFF7-1546795A4725 Q36993953-A30949A8-C47A-45A3-B4BD-0300E993DE59 Q37121420-0D891EB4-CC49-4E4F-BBA3-6D16B73B6500 Q37544670-FEC214A1-0605-48B6-B490-A78FE2A2EA4E Q37705207-0975C340-1ABC-4F6A-971F-C9411AE02F99 Q38274889-197ED86D-010D-46EF-B762-D320669C9138 Q38693891-B76B0B21-32A5-4294-8DA2-99B77EB0CBF1 Q38992313-44FD911F-1804-4BD1-B801-139A6330898F Q39253660-EC1D7BED-0D02-4114-8D72-3C51779DC454 Q39339661-19F09290-C883-4541-B365-352C09D163FA Q39356376-FFBF3793-78A6-46B6-9BBC-224D0E3A82DE Q39691970-9FB4FF10-C82D-4C8D-9DF7-291D83FBB4BA Q40459351-AA7B1F5E-A821-4F50-80F4-104779D70DE0 Q41824328-8D1CBD85-1AA8-4930-82C1-23008A2342F3 Q42088565-250FF995-C3EB-48AC-82A6-8EFA4A042BA3

P2860

Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent

http://www.wikidata.org/entity/Q24656023

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Inhibition of human immunodefi ...... ovel cyclophilin binding agent

@ast

Inhibition of human immunodefi ...... ovel cyclophilin binding agent

@en

Inhibition of human immunodefi ...... ovel cyclophilin binding agent

@nl

type

label

Inhibition of human immunodefi ...... ovel cyclophilin binding agent

@ast

Inhibition of human immunodefi ...... ovel cyclophilin binding agent

@en

Inhibition of human immunodefi ...... ovel cyclophilin binding agent

@nl

altLabel

Inhibition of Human Immunodefi ...... ovel Cyclophilin Binding Agent

@en

prefLabel

Inhibition of human immunodefi ...... ovel cyclophilin binding agent

@ast

Inhibition of human immunodefi ...... ovel cyclophilin binding agent

@en

Inhibition of human immunodefi ...... ovel cyclophilin binding agent

@nl

P1433

Q24656023-1527515E-E04D-4B3F-B9FE-FD58641B0701

P1476

Q24656023-0E8F2F7B-31A1-48C1-A7F7-3181F2160101

P2093

Q24656023-2857B532-D2B4-4D63-A858-D2D2024C76ED

Q24656023-2960312F-3FA4-440E-8A69-864CAF0E7347

Q24656023-48C25F1D-2537-4440-89B1-361AFB4C614D

Q24656023-4CDB0A6C-0F0D-4DB6-BB3F-2C2BFC11EBFA

Q24656023-89259D0A-72DA-4C14-8C13-5458E35A9C36

Q24656023-8A96ED37-1C91-4C32-899F-4AC7A5F3108A

Q24656023-93C9EDC2-0D2E-46FB-8687-C94AEE18FD35

Q24656023-A0D1E4EA-95D4-4963-8701-BF3179EC0F8C

Q24656023-AA6ECAA5-D073-4907-B51C-2F0A79C49786

Q24656023-D4C65BD3-41CD-4794-88A3-45B064B7E878

P2860

Q24656023-0BEA96BA-E5D1-4C90-8C3B-4A590AABAEC3

Q24656023-0C384235-ECC9-49CB-A922-30A4A07B87E0

Q24656023-0ED0CB4F-D1DE-453B-9DC5-A22BCBC71D91

Q24656023-1167F84B-7075-497B-8C5E-68E4945C63C8

Q24656023-122295A5-9D7C-46A6-BF00-823C17567991

Q24656023-14A7AEE2-235B-473D-953D-C0C8D1A1D8BF

Q24656023-1FDF4D06-DB31-4D63-9963-645DE184BDEB

Q24656023-20503A48-C450-46B7-A167-969B08B40A96

Q24656023-247D05EB-4D0F-4788-90F6-4191F509BDDA

Q24656023-24AEEB67-591F-4C02-8633-079A0718D987

P304

Q24656023-FF4E444C-6AFD-4786-882F-D90E6229539A

P31

Q24656023-0BDE435F-80FD-48D9-B085-10796B60918C

P3181

Q24656023-B35B5C6F-8665-4F6C-8D4F-D3479B7A192E

P356

Q24656023-5E6097FF-7990-428C-B9DC-29C3FD307F96

P407

Q24656023-7F9DD950-9B3F-4529-AD87-6E802A2B376F

P433

Q24656023-B7CB9CAC-20CB-4349-8740-CC39668DF331

P478

Q24656023-7FBAEBB2-BA25-4771-AEB8-CABD91F25CB0

P50

Q24656023-1C7D91EA-227F-4B05-A88D-6DD042AC3B87

Q24656023-C3B75E02-3C42-49D8-A9A5-B86C8DE43AC9

Q24656023-C81D82BB-65BE-49EE-BE0A-2B3224DBC5BD

Q24656023-D253F2C8-FE81-4242-ACB7-C77EC1902A41

Q24656023-FDFF0BC6-1B58-4517-A654-F5A8E35522E1

P577

Q24656023-D05C2E2B-4F53-4A1F-9699-9146B7CF7E4F

P698

Q24656023-4198AA52-DB50-464B-AAE6-20E6F8D1ABDF

P921

Q24656023-35EBED8C-250B-4B77-BDAA-B47806718A76

P932

Q24656023-12025E7C-3694-4674-AD6D-064DE5F7445F

P3181

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Inhibition of human immunodefi ...... ovel cyclophilin binding agent

@en

P2093

Brigitte Rosenwirth

http://www.w3.org/2001/XMLSchema#string

Jean-Maurice Dumont

http://www.w3.org/2001/XMLSchema#string

Kamel Besseghir

http://www.w3.org/2001/XMLSchema#string

Luke A Pallansch

http://www.w3.org/2001/XMLSchema#string

Marie-Pierre de Béthune

http://www.w3.org/2001/XMLSchema#string

Michael D Bobardt

http://www.w3.org/2001/XMLSchema#string

Philippe A Gallay

http://www.w3.org/2001/XMLSchema#string

Pietro Scalfaro

http://www.w3.org/2001/XMLSchema#string

Roger G Ptak

http://www.w3.org/2001/XMLSchema#string

Roland M Wenger

http://www.w3.org/2001/XMLSchema#string

P2860

Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells

Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes

Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin

The Imidazopyrrolopyridine Analogue AG110 Is a Novel, Highly Selective Inhibitor of Pestiviruses That Targets the Viral RNA-Dependent RNA Polymerase at a Hot Spot for Inhibition of Viral Replication

Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid

Cyclophilin, TRIM5, and innate immunity to HIV-1

Determination of enzymatic catalysis for the cis-trans-isomerization of peptide binding in proline-containing peptides

AIDS and related syndromes as a viral-induced autoimmune disease of the immune system: an anti-MHC II disorder. Therapeutic implications

P304

1302-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2143464

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/AAC.01324-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

Andrew P Halestrap

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18212100

http://www.w3.org/2001/XMLSchema#string

P921

P932

2292519

http://www.w3.org/2001/XMLSchema#string